Cytosorbents Crp Net Income
| CTSO Stock | USD 0.75 0.02 2.74% |
As of the 1st of March, Cytosorbents Crp shows the Risk Adjusted Performance of 0.0395, mean deviation of 3.31, and Downside Deviation of 5.15. Cytosorbents Crp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Cytosorbents Crp Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.808 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -18.6 M | -17.7 M | |
| Net Loss | -18.6 M | -19.6 M | |
| Net Loss | -29.5 M | -28.1 M | |
| Net Loss | (0.34) | (0.36) | |
| Net Income Per E B T | 0.83 | 0.75 |
Cytosorbents | Net Income | Build AI portfolio with Cytosorbents Stock |
Evaluating Cytosorbents Crp's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Cytosorbents Crp's fundamental strength.
Latest Cytosorbents Crp's Net Income Growth Pattern
Below is the plot of the Net Income of Cytosorbents Crp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cytosorbents Crp financial statement analysis. It represents the amount of money remaining after all of Cytosorbents Crp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cytosorbents Crp's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytosorbents Crp's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (20.72 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cytosorbents Net Income Regression Statistics
| Arithmetic Mean | (14,104,015) | |
| Coefficient Of Variation | (66.45) | |
| Mean Deviation | 7,922,797 | |
| Median | (11,938,875) | |
| Standard Deviation | 9,372,758 | |
| Sample Variance | 87.8T | |
| Range | 32.7M | |
| R-Value | (0.80) | |
| Mean Square Error | 34T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | (1,481,033) | |
| Total Sum of Squares | 1405.6T |
Cytosorbents Net Income History
Other Fundumenentals of Cytosorbents Crp
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cytosorbents Crp Net Income component correlations
Cytosorbents Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cytosorbents Crp is extremely important. It helps to project a fair market value of Cytosorbents Stock properly, considering its historical fundamentals such as Net Income. Since Cytosorbents Crp's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cytosorbents Crp's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cytosorbents Crp's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Health Care Equipment & Supplies sector continue expanding? Could Cytosorbents diversify its offerings? Factors like these will boost the valuation of Cytosorbents Crp. Projected growth potential of Cytosorbents fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cytosorbents Crp data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.18) | Revenue Per Share | Quarterly Revenue Growth 0.101 | Return On Assets | Return On Equity |
Investors evaluate Cytosorbents Crp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytosorbents Crp's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Cytosorbents Crp's market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytosorbents Crp's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytosorbents Crp should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytosorbents Crp's market price signifies the transaction level at which participants voluntarily complete trades.
Cytosorbents Crp 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cytosorbents Crp's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cytosorbents Crp.
| 12/01/2025 |
| 03/01/2026 |
If you would invest 0.00 in Cytosorbents Crp on December 1, 2025 and sell it all today you would earn a total of 0.00 from holding Cytosorbents Crp or generate 0.0% return on investment in Cytosorbents Crp over 90 days. Cytosorbents Crp is related to or competes with Icecure Medical, Tela Bio, Spectral, Sensus Healthcare, Neuroone Medical, Baird Medical, and Electrocore LLC. Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood p... More
Cytosorbents Crp Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cytosorbents Crp's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cytosorbents Crp upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.15 | |||
| Information Ratio | 0.0226 | |||
| Maximum Drawdown | 29.4 | |||
| Value At Risk | (7.41) | |||
| Potential Upside | 7.58 |
Cytosorbents Crp Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cytosorbents Crp's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cytosorbents Crp's standard deviation. In reality, there are many statistical measures that can use Cytosorbents Crp historical prices to predict the future Cytosorbents Crp's volatility.| Risk Adjusted Performance | 0.0395 | |||
| Jensen Alpha | 0.125 | |||
| Total Risk Alpha | (0.33) | |||
| Sortino Ratio | 0.0221 | |||
| Treynor Ratio | 0.225 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cytosorbents Crp's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cytosorbents Crp March 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0395 | |||
| Market Risk Adjusted Performance | 0.235 | |||
| Mean Deviation | 3.31 | |||
| Semi Deviation | 3.93 | |||
| Downside Deviation | 5.15 | |||
| Coefficient Of Variation | 2469.79 | |||
| Standard Deviation | 5.04 | |||
| Variance | 25.36 | |||
| Information Ratio | 0.0226 | |||
| Jensen Alpha | 0.125 | |||
| Total Risk Alpha | (0.33) | |||
| Sortino Ratio | 0.0221 | |||
| Treynor Ratio | 0.225 | |||
| Maximum Drawdown | 29.4 | |||
| Value At Risk | (7.41) | |||
| Potential Upside | 7.58 | |||
| Downside Variance | 26.57 | |||
| Semi Variance | 15.46 | |||
| Expected Short fall | (4.40) | |||
| Skewness | 1.17 | |||
| Kurtosis | 4.66 |
Cytosorbents Crp Backtested Returns
As of now, Cytosorbents Stock is dangerous. Cytosorbents Crp secures Sharpe Ratio (or Efficiency) of 0.0219, which signifies that the company had a 0.0219 % return per unit of risk over the last 3 months. We have found thirty technical indicators for Cytosorbents Crp, which you can use to evaluate the volatility of the firm. Please confirm Cytosorbents Crp's Mean Deviation of 3.31, risk adjusted performance of 0.0395, and Downside Deviation of 5.15 to double-check if the risk estimate we provide is consistent with the expected return of 0.0996%. Cytosorbents Crp has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.86, which signifies possible diversification benefits within a given portfolio. Cytosorbents Crp returns are very sensitive to returns on the market. As the market goes up or down, Cytosorbents Crp is expected to follow. Cytosorbents Crp right now shows a risk of 4.56%. Please confirm Cytosorbents Crp value at risk and the relationship between the skewness and relative strength index , to decide if Cytosorbents Crp will be following its price patterns.
Auto-correlation | 0.45 |
Average predictability
Cytosorbents Crp has average predictability. Overlapping area represents the amount of predictability between Cytosorbents Crp time series from 1st of December 2025 to 15th of January 2026 and 15th of January 2026 to 1st of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cytosorbents Crp price movement. The serial correlation of 0.45 indicates that just about 45.0% of current Cytosorbents Crp price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.45 | |
| Spearman Rank Test | -0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cytosorbents Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cytosorbents Crp reported net income of (20.72 Million). This is 106.07% lower than that of the Health Care Equipment & Supplies sector and 108.7% lower than that of the Health Care industry. The net income for all United States stocks is 103.63% higher than that of the company.
Cytosorbents Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytosorbents Crp's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytosorbents Crp could also be used in its relative valuation, which is a method of valuing Cytosorbents Crp by comparing valuation metrics of similar companies.Cytosorbents Crp is currently under evaluation in net income category among its peers.
Cytosorbents Crp Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cytosorbents Crp from analyzing Cytosorbents Crp's financial statements. These drivers represent accounts that assess Cytosorbents Crp's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cytosorbents Crp's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 181.7M | 67.5M | 49.6M | 49.5M | 44.6M | 42.4M | |
| Enterprise Value | 143.4M | 63.6M | 53.8M | 73.1M | 65.8M | 92.1M |
Cytosorbents Crp Institutional Holders
Institutional Holdings refers to the ownership stake in Cytosorbents Crp that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Cytosorbents Crp's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cytosorbents Crp's value.| Shares | Advisor Group Holdings, Inc. | 2025-06-30 | 130.4 K | Ubs Group Ag | 2025-06-30 | 122.3 K | Renaissance Technologies Corp | 2025-06-30 | 116.6 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 105.4 K | Nwf Advisory Services Inc | 2025-03-31 | 104.1 K | Northern Trust Corp | 2025-06-30 | 91.6 K | Key Client Fiduciary Advisors, Llc | 2025-06-30 | 78.5 K | Kestra Advisory Services, Llc | 2025-06-30 | 70.9 K | Stifel Financial Corp | 2025-06-30 | 48 K | Avenir Corporation | 2025-06-30 | 5.1 M | Skylands Capital, Llc | 2025-06-30 | 2.6 M |
Cytosorbents Fundamentals
| Return On Equity | -0.93 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 66.86 M | ||||
| Shares Outstanding | 62.8 M | ||||
| Shares Owned By Insiders | 15.77 % | ||||
| Shares Owned By Institutions | 27.02 % | ||||
| Number Of Shares Shorted | 2.04 M | ||||
| Price To Earning | (16.30) X | ||||
| Price To Book | 5.24 X | ||||
| Price To Sales | 1.28 X | ||||
| Revenue | 35.59 M | ||||
| Gross Profit | 26.18 M | ||||
| EBITDA | (15.22 M) | ||||
| Net Income | (20.72 M) | ||||
| Cash And Equivalents | 30.16 M | ||||
| Cash Per Share | 0.69 X | ||||
| Total Debt | 26.89 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 0.14 X | ||||
| Cash Flow From Operations | (14.43 M) | ||||
| Short Ratio | 25.21 X | ||||
| Earnings Per Share | (0.18) X | ||||
| Target Price | 5.25 | ||||
| Number Of Employees | 149 | ||||
| Beta | 1.41 | ||||
| Market Capitalization | 47.26 M | ||||
| Total Asset | 47.37 M | ||||
| Retained Earnings | (304.01 M) | ||||
| Working Capital | 11.78 M | ||||
| Current Asset | 9.05 M | ||||
| Current Liabilities | 5 M | ||||
| Net Asset | 47.37 M |
About Cytosorbents Crp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytosorbents Crp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytosorbents Crp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytosorbents Crp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cytosorbents Crp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytosorbents Crp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytosorbents Crp will appreciate offsetting losses from the drop in the long position's value.Moving against Cytosorbents Stock
The ability to find closely correlated positions to Cytosorbents Crp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytosorbents Crp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytosorbents Crp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytosorbents Crp to buy it.
The correlation of Cytosorbents Crp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytosorbents Crp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytosorbents Crp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytosorbents Crp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Will Health Care Equipment & Supplies sector continue expanding? Could Cytosorbents diversify its offerings? Factors like these will boost the valuation of Cytosorbents Crp. Projected growth potential of Cytosorbents fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cytosorbents Crp data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.18) | Revenue Per Share | Quarterly Revenue Growth 0.101 | Return On Assets | Return On Equity |
Investors evaluate Cytosorbents Crp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Cytosorbents Crp's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Cytosorbents Crp's market price to deviate significantly from intrinsic value.
It's important to distinguish between Cytosorbents Crp's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytosorbents Crp should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Cytosorbents Crp's market price signifies the transaction level at which participants voluntarily complete trades.